Evening Update: Schizophrenia Trials - Past, Present & Future Implications for Clinical Practice
Tuesday 09th February 2021Virtual Event via Zoom
5.45pm Registration/Login, 6.00pm Welcome and 8.00pm Close
More than 100 years ago Kraepelin described the psychotic disorder with poor prognosis which later gained the term schizophrenia. Advent of antipsychotics in the 20th century changed the perception of the illness to some degree. Antipsychotic medications are the mainstay of treatment in schizophrenia and their efficacy is supported by variable quality of evidence.
Led by Dr Prakash Hosalli, Consultant Psychiatrist for Leeds and York Partnership NHS Foundation Trust, the talk will cover the quality of clinical trials in schizophrenia in particular on antipsychotic medications. It gives an overview of the important developments in the area of antipsychotic medications and landmark clinical trials.
After attending this course delegates will be able to:
- Get an overview of quality of clinical trials in schizophrenia
- Understand the evidence base supporting antipsychotics efficacy in schizophrenia
- Have enhanced confidence iin the decisions about antipsychotic use in clinical practice
- Recap summaries of major studies in schizophrenia